Polatuzumab vedotin
- Generic Name
- Polatuzumab vedotin
- Brand Names
- Polivy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1313206-42-6
- Unique Ingredient Identifier
- KG6VO684Z6
- Background
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrul...
- Indication
Polatuzumab vedotin is used in combination with bendamustine and rituximab to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. In Canada, this indication is approved for patients who are not eligible for autologous stem cell transplant and have received at least one p...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma, High-grade B Cell Lymphoma (HGBCL), Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT05171647
- Locations
- 🇺🇸
Ironwood cancer and research center, Chandler, Arizona, United States
🇺🇸City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 42
- Registration Number
- NCT05169658
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 80
- Registration Number
- NCT04914741
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Czech Lymphoma Study Group
- Target Recruit Count
- 21
- Registration Number
- NCT04913103
- Locations
- 🇨🇿
University Hospital Hradec Králové, Hradec Králové, Czechia
🇨🇿University Hospital Brno, Brno, Czechia
🇨🇿University Hospital Kralovske Vinohrady, Prague 10, Czechia
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Local Institution - 501, Adelaide, South Australia, Australia
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 334
- Registration Number
- NCT04833114
- Locations
- 🇩🇪
Universitätsklinikum Jena, Jena, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪DIAKO Ev.Diakonie-Krankenhaus gemeinnützige GmbH, Bremen, Germany
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04790903
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
🇫🇷CHU Montpellier - Saint ELOI, Montpellier, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT04679012
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸Mount Sinai- Icahn School of Medicine, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.